Mylan Fact Sheet
`
`Our Mission
`At Mylan, we are committed
`to setting new standards in
`healthcare. Working together
`around the world to provide
`7 billion people access to high
`quality medicine, we:
`• Innovate to satisfy unmet needs
`• Make reliability and service
`excellence a habit
`• Do what’s right, not what’s easy
`• Impact the future through
`passionate global leadership
`
`Creating better health for a
`better world. That’s what
`inspires Mylan’s mission of
`providing quality healthcare
`to the world’s 7 billion people,
`one person at a time.
`
`
`
`Mylan is one of the world’s leading global pharmaceutical companies.
`Our medicines include generic, brand name and over-the-counter
`products in a variety of dosage forms and therapeutic categories,
`such as difficult-to-manufacture injectables, transdermal patches,
`topicals and HIV/AIDS antiretroviral (ARV) therapies. The company
`has innovative research and development capabilities and is one of
`the world’s largest active pharmaceutical ingredient (API) manufacturers.
`Mylan applies one global quality standard to all of our medications
`regardless of where they are produced.
`
` 2015 Revenue: $9.45 billion* Ticker: NASDAQ, TASE: MYL
`
`
`Global workforce: more than 40,000
`
` Products: a global market portfolio of more than 2,700 separate products
`
`Product submissions: more than 3,400 new product submissions pending
`regulatory approval around the world
`
`Global presence: sell products in more than 165 countries and territories
`
`U.S. presence: one out of every 13 prescriptions dispensed in the U.S. – brand
`name or generic – is a Mylan product
`
`Manufacturing presence: operate more than 50 facilities around the globe
`
` R&D capabilities: include an extensive range of dosage forms and delivery
`systems, including oral solid doses, transdermal patches, injectables, respiratory
`inhalants, dermatologics, topicals, soft gel capsules, nasal sprays, solutions,
`suspensions, ophthalmics, ARVs and APIs
`
`ARV access: approximately 50% of people living with HIV/AIDS worldwide
`who are receiving treatment depend on a Mylan product
`
`Notable: member of S&P 500
`
`Fast Facts
`
`Page 1
`
`Mylan v. Genentech
`IPR2016-00710
`Genentech Exhibit 2097
`
`
`
`*Not inclusive of Renaissance/Meda
`
`
`

`
`OUR VALUES
`
`INNOVATION | INTEGRITY | RELIABILITY | SERVICE | TEAMWORK
`
`EUROPE
`(cid:39) Cambridge, U.K.
`(cid:3)
`(cid:81)(cid:3)(cid:3) Châtillon, France
`
`(cid:81)(cid:3) Cologne, Germany
`
`(cid:81) Confienza, Italy
`
` (cid:39)(cid:3)(cid:81)(cid:3)(cid:79)(cid:3)(cid:3) Dublin, Ireland (2)
` (cid:39)(cid:3)(cid:86)(cid:3)(cid:3) Galway, Ireland
`
`(cid:81)(cid:3)(cid:3) Komarom, Hungary
`
`(cid:79) Merignac, France
`
`(cid:81)(cid:3)(cid:3) Meyzieu, France
`
`(cid:39) Monza, Italy
`
`(cid:39) Radebeul, Germany
`
`(cid:39) Sandwich, U.K.
`
`(cid:81) Troisdorf, Germany
`(cid:86)(cid:3)(cid:3) Warsaw, Poland
`(cid:3)
`
`JAPAN
`
`(cid:81)(cid:3)(cid:3) Katsuyama
`(cid:3)
`(cid:3) (cid:39)(cid:3)(cid:81)(cid:3)(cid:3) Kawagoe
`
`AUSTRALIA
`
`(cid:3)
`
`(cid:81)(cid:3)(cid:3) Carole Park, Queensland
`
`INDIA
`
`(cid:3) (cid:39)(cid:3)(cid:81)(cid:3)(cid:3) Ahmedabad
`(cid:81)(cid:3)(cid:3) Aurangabad
`(cid:3)
`(cid:3) (cid:39)(cid:3)(cid:86)(cid:3)(cid:3) Bangalore (5)
`(cid:81)(cid:3)(cid:3) Daman
`(cid:3)
`(cid:86)(cid:3)(cid:3) Hosur
`(cid:3)
`(cid:3) (cid:39)(cid:3)(cid:88)(cid:3)(cid:3) Hyderabad (4)
`(cid:81)(cid:3)(cid:3) Indore
`(cid:3)
`(cid:81)(cid:3)(cid:3) Jadcherla
`(cid:3)
`(cid:81)(cid:3)(cid:3)(cid:3)Jaggaiahpet
`(cid:3)
`(cid:88)(cid:3)(cid:3) Mumbai
`(cid:3)
`(cid:81)(cid:3)(cid:3) Nashik
`(cid:3)
`(cid:81)(cid:3)(cid:3) Sarigam (2)
`(cid:3)
`(cid:3) (cid:86)(cid:3)(cid:88)(cid:3)(cid:3) Vizag (4)
`
`
`
`(cid:88)(cid:3)Active Pharmaceutical Ingredients: 9
`
`(cid:86)(cid:3)Injectables: 9
`
`(cid:39) Research and Development: 14 (cid:3)
`Powerful Global Commercial Presence*
`U.S.
`Europe
`One in 13 prescriptions in the U.S.,
`Mylan holds leadership positions in several
`brand name or generic, is filled with a
`key European markets, including France,
`Mylan product
`Italy, the Netherlands, Portugal and the U.K.
`India
`Japan
`Mylan represents 20% of the
`Mylan has been the fastest grower in the Japan
`Hepatitis C market share in India
`generics market for the last three years†
`Canada
`Australia
`Mylan products are sold in eight out of 10
`Mylan is the No. 1 supplier by volume to
`pharmacies in Canada
`Australia’s national pharmaceuticals program
`
`Leadership
`
`* Not inclusive of Renaissance/Meda
`† Excluding authorized generics
`
`
`Robert J. Coury
`Chairman
`
`Heather Bresch
`Chief Executive Officer
`
`Rajiv Malik
`President
`
`Ken Parks
`Chief Financial Officer
`
`Tony Mauro
`Chief Commercial Officer
`
`Media Relations:
`+1.724.514.1968
`Communications@mylan.com
`
`Investor Relations:
`+1.724.514.1813
`InvestorRelations@mylan.com
`
` NORTH AMERICA
`
`
` (cid:81)(cid:3)(cid:3) Caguas, Puerto Rico
`(cid:79) Decatur, Illinois
`
` (cid:39)(cid:3)(cid:81)(cid:3) Morgantown, West Virginia
`
`(cid:81)(cid:3)(cid:3)(cid:3)Rockford, Illinois
` (cid:39)(cid:3)(cid:79) Saint-Hubert, Quebec
` (cid:39)(cid:3)(cid:79) San Antonio, Texas (3)
` (cid:39)(cid:3)(cid:79)(cid:3)(cid:3) St. Albans, Vermont
`
`(cid:79)(cid:3)(cid:3) Sugar Land, Texas
`
`
`
`
`
`(cid:3)(cid:3)(cid:81)(cid:3)Oral Solid Doses: 23 (cid:79)(cid:3)Complex Products: 9
`
`Our Evolution
`1961
`
`Founded by Milan “Mike” Puskar and
`Don Panoz in White Sulphur Springs,
`West Virginia, U.S.
`1973
`
`Became a publicly traded company
`1984
`
`Received our first branded product approval
`2002
`
`Generated more than $1 billion
`in revenue for the first time
`2007
`
`Went global with the acquisitions
`of Matrix and Merck Generics
`2012
`
`Helped champion the U.S. Food and Drug
`Administration Safety and Innovation Act
`2013
`
`Acquired Agila Specialties and
`became a global injectables leader
`2015
`Acquired Abbott’s non-U.S. developed markets
`specialty and branded generics business
`Acquired certain businesses from Famy Care
`to become a global women’s healthcare leader
`2016
`Acquired topicals-focused specialty and
`generics business from Renaissance
`Acquired Meda, a leading international
`specialty pharmaceutical company
`
`Stay Connected
`
`©2016 Mylan N.V. All rights reserved. (November 2016)
`Better Health for a Better World® and the Mylan logo
`are registered trademarks of Mylan Inc.
`NON-2016-0806
`
`Mylan.com
`
`Page 2
`
`@MylanNews
`@MylanCareers